- and in
general can be
avoided with the use of
synthetic heparins. Not all
patients with
heparin antibodies will
develop thrombocytopenia. Also, a benign...
- (December 2007). "Intravenous low-molecular-weight
heparins compared with
unfractionated heparin in
percutaneous coronary intervention: quantitative...
- is
generally given subcutaneously.
Commonly used low
molecular weight heparins are enoxaparin, dalteparin,
nadroparin and tinzaparin. In HIT, the platelet...
- The
enzyme heparin lyase (EC 4.2.2.7)
catalyzes the
following process:
Eliminative cleavage of
polysaccharides containing (1→4)-linked D-glucuronate or...
-
Several anticoagulants are available. Warfarin,
other coumarins, and
heparins have long been used.
Since the 2000s,
several agents have been introduced...
-
Heparin necrosis is a
cutaneous condition and
usually occurs between days 5 and 10 of
heparin therapy.
Warfarin necrosis List of
cutaneous conditions...
-
Heparin mimicking polymers are
synthetic compounds that
possess similar characteristics to
heparin, that is it can be used
clinically as an anticoagulant...
- Taurolidine/
heparin, sold
under the
brand name Defencath, is a fixed-dose
combination catheter lock
solution used for
central venous catheter instillation...
-
Heparin cofactor II (HCII), a
protein encoded by the SERPIND1 gene, is a
coagulation factor that
inhibits IIa, and is a
cofactor for
heparin and dermatan...
-
others between May and December, 2006. He
killed with a
hidden vial of
heparin — a blood-thinning drug
causing internal bleeding when
administered in...
